The lower odds of prior RA in patients with AD than those without AD is thought to be associated with the use of non-steroidal anti-inflammatory drugs (NSAIDs) or the upregulation of granulocyte macrophage colony-stimulating factors (GM-CSFs) in patients with RA. The gene discussed is CSF2; the disease is rheumatoid arthritis.